It does this by measuring the time on the cancer pathway from the point a patient was suspected of having cancer rather than the point at which the decision to treat is made.
Mae’n gwneud hyn drwy fesur yr amser ar y llwybr canser o’r cyfnod pan fydd amheuaeth o ganser yn hytrach na’r adeg y gwneir penderfyniad i roi triniaeth.